Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safet — Jonathan Kil (SOUND PHARMAC
Project Summary/Abstract SARS-CoV-2 (nCoV2) has been identified as the viral etiology of COVID-19, a pandemic respiratory disease that has no effective treatment and growing morbidity and mortality. A
| Project title | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safet |
|---|---|
| Project number | 1U01TR003853-01 |
| PI name | Jonathan Kil |
| Institution | SOUND PHARMACEUTICALS, INC. |
| Funding mechanism | U01 |
| Agency | NCATS |
| Award amount | $3.08M |
| Fiscal year | 2021 |
| Project start | 2021-04-06T00:00:00 |
| Project end | 2023-12-31T00:00:00 |
| Abstract | Project Summary/Abstract SARS-CoV-2 (nCoV2) has been identified as the viral etiology of COVID-19, a pandemic respiratory disease that has no effective treatment and growing morbidity and mortality. A |
| Key terms | <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><21+ years old><Academic Medical Centers |
$799/mo
Try GrantRadar →